Major Bleeding Risk Assessment in Patients with Cancer-Associated Venous Thromboembolism Treated with DOACs: Data from a Multicenter Cohort
Einschätzung des Risikos für schwere Blutungen bei Patient:innen mit krebsassoziierter venöser Thromboembolie unter DOACs: Daten aus einer multizentrischen Kohorte
Thrombosis and Haemostasis · 01.03.2026 · 126 (03) · 276-286
DOI: 10.1055/a-2605-9015 ↗Auf einen Blick
Bei 823 Patient:innen mit CAT unter DOACs traten 44 schwere Blutungen auf. Bestehende Blutungsrisikoscores zeigten nur eine mäßige Vorhersageleistung.
Fragestellung
Wie gut sagen neun Blutungsrisikoscores schwere Blutungen bei CAT-Patient:innen unter DOACs voraus, und welche Faktoren sind mit Blutungen verbunden?
Methode
Multizentrische Beobachtungsstudie bei CAT-Patient:innen unter DOACs; Bewertung von neun Blutungsrisikoscores und Entwicklung des Perform-Scores.
Ergebnisse
823 Patient:innen, mittlere Nachbeobachtung 1,6 Jahre. Schwere Blutungen: 44 Fälle (3,4 % pro Patientenjahr). c-Statistiken der Scores 0,513–0,606; Perform-Score 0,678.
Schlussfolgerung der Autor:innen
Bei CAT-Patient:innen unter DOACs waren unresezierter gastrointestinaler Krebs sowie Steroide oder Antimetabolite mit höherem Blutungsrisiko verbunden; die Autoren sehen Bedarf an weiteren Studien.
Kernaussagen
- 44 schwere Blutungen bei 823 Patient:innen
- Scores mit begrenzter Vorhersageleistung
- Perform-Score besser, aber weiter suboptimal
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Multizentrische Studie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.03.2026. Verfasst von Maria Cristina Vedovati und 14 weiteren Autor:innen. Beteiligte Einrichtung: Internal, Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Venous Thromboembolism, Neoplasms, Hemorrhage, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
In cancer-associated venous thromboembolism (CAT), extended anticoagulation should be considered when the risk–benefit profile is favorable. However, optimal predictors of major bleeding (MB) remain unclear. This multicenter observational study included CAT patients treated with direct oral anticoagulants (DOACs). Study objectives were: (i) assess the performance of nine bleeding risk scores (ATRIA, CAT-BLEED, CHAP, DOAC, HAS-BLED, Kuijer, ORBIT, RIETE, VTE-BLEED), (ii) identify predictors of MB (ISTH definition), and (iii) propose an improved bleeding risk model (Perform score). Overall, 823 patients were followed (mean 1.6 years). MB occurred in 44 cases (3.4% per patient-year). The predictive performance of bleeding risk scores was modest (c-statistics range 0.513–0.606). Risk factors included increasing age (HR 1.04, 95% CI 1.00–1.07), use of steroids (HR 2.69, 95% CI 1.34–5.40), antimetabolites (HR 2.51, 95% CI 1.28–4.93), and unresected gastrointestinal cancer (HR 7.30, 95% CI 1.70–31.30). Conversely, prior cancer surgery (HR 0.41, 95% CI 0.20–0.82) and anticancer hormones (HR 0.22, 95% CI 0.05–0.92) showed a possible protective effect toward MB risk. The Perform score provided a slight enhancement in risk prediction (c-statistics 0.678), but remained suboptimal. In this real-world cohort of CAT patients treated with DOACs, unresected gastrointestinal cancer and use of steroids or antimetabolites were associated with increased MB risk, while prior cancer surgery and anticancer hormones were linked to a lower risk. These factors, not considered in current bleeding risk scores, may refine bleeding prediction. Further studies should clarify their role in guiding anticoagulation decisions and improving personalized risk assessment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Internal, Vascular and Emergency Medicine - Stroke Unit, University of Perugia, Perugia, Italy.
- Department of Geriatric, Orthopedic, and Rheumatologic Sciences, University Polyclinic Foundation A. Gemelli IRCCS, Rome, Italy.
- Thrombosis and Hemorragic Diseases Unit, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
- Interdisciplinary Internal Medicine, Careggi University Hospital, Florence, Italy.
- First Chair of Internal Medicine and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy.
- Medicine II Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy.
ORCID-Profile: Maria Cristina Vedovati, Rosa Talerico, Elena Campello, Roberto Pola
Zitieren
APA
Vedovati, M. C., Talerico, R., Sacco, C., Mazzetti, M., Campello, E., Birocchi, S., Beccatini, S., Porfidia, A., Caprari, R., Lodigiani, C., Simioni, P., Podda, G. M., Mastandrea, I., Becattini, C., & Pola, R. (2026). Major Bleeding Risk Assessment in Patients with Cancer-Associated Venous Thromboembolism Treated with DOACs: Data from a Multicenter Cohort. Thrombosis and Haemostasis, 126(03), 276-286. https://doi.org/10.1055/a-2605-9015
Vancouver
Vedovati MC, Talerico R, Sacco C, Mazzetti M, Campello E, Birocchi S, et al. Major Bleeding Risk Assessment in Patients with Cancer-Associated Venous Thromboembolism Treated with DOACs: Data from a Multicenter Cohort. Thrombosis and Haemostasis. 2026;126(03):276-286. doi:10.1055/a-2605-9015
BibTeX
@article{Vedovati2026,
author = {Vedovati, Maria Cristina and Talerico, Rosa and Sacco, Clara and Mazzetti, Matteo and Campello, Elena and Birocchi, Simone and Beccatini, Sofia and Porfidia, Angelo and Caprari, Rachele and Lodigiani, Corrado and Simioni, Paolo and Podda, Gian Marco and Mastandrea, Isabella and Becattini, Cecilia and Pola, Roberto},
title = {Major Bleeding Risk Assessment in Patients with Cancer-Associated Venous Thromboembolism Treated with DOACs: Data from a Multicenter Cohort},
journal = {Thrombosis and Haemostasis},
year = {2026},
volume = {126},
number = {03},
pages = {276--286},
doi = {10.1055/a-2605-9015}
}
EUVIMED